TCM
NTLA icon

Teza Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Teza Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,683
Closed -$83.1K – 440
2025
Q1 		$83.1K Sell
11,683
-14,382
-55% -$145K 0.04% 394
2024
Q4 		$304K Buy
26,065
+11,107
+74% +$173K 0.05% 354
2024
Q3 		$307K Sell
14,958
-5,137
-26% -$118K 0.03% 475
2024
Q2 		$450K Buy
+20,095
New +$478K 0.06% 376

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Teza Capital Management's NTLA Position: Q2 2025 in Review

Teza Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 11,683 shares — an estimated $83.1K sold.

Teza Capital Management first reported a position in NTLA in Q2 2024 and held it in 4 quarters. The position peaked at $450K in Q2 2024. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Teza Capital Management reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 11,683 Intellia Therapeutics shares in Q2 2025, an estimated $83.1K.
  • Teza Capital Management first reported a position in Intellia Therapeutics in Q2 2024 and held it in 4 quarters.
  • Teza Capital Management's Intellia Therapeutics position peaked at $450K in Q2 2024.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.